This new vaccine for cats prevents allergic reactions in humans

Zürich researchers have published preclinical data in The Journal of Allergy and Clinical Immunology about a different kind of cat allergy solution: a vaccine that is inoculated into the cat, rather than into the human.

The most common cat allergen is called “Fel d 1”, produced largely by the cat’s sebaceous glands and found in feline saliva, anal glands, sebaceous glands, skin and fur.

Fel-CuMVTT, which the Swiss company HypoPet will market as a HypoCat vaccine, has been developed through a collaboration between researchers from the Latvian Biomedical Research and Study Center in Riga and the University of Zurich veterinary school, together with scientists at the Zurich Center for Functional Genomics.

The vaccine can produce high levels of antibodies in cats. These antibodies can bind to and neutralize the Fel d 1 allergen produced by the animals.

In addition to the vaccine being reported to be effective, it is also reported to have been “well tolerated without any overt toxicity” for feline test subjects. The published data is obtained from four separate studies involving 54 cats.

The benefits of effective cat allergy treatment are twofold. First of all, these allergies are not only annoying, but an allergy to cats in children is understood to be an important factor in the development of childhood asthma. A simple treatment of three doses of the vaccine, as administered in the trials, could alleviate the suffering of cat owners and the risk to children.

Leave a Reply

Your email address will not be published. Required fields are marked *